Financial Barriers to Menopause Treatment Highlighted in Recent Survey
In a new survey conducted by GoodRx Research, findings reveal that many women are facing significant financial obstacles when it comes to accessing menopause treatments. While the majority spend less than $50 monthly on related care, the costs remain a prevalent barrier, prompting some to delay or forgo necessary treatments entirely.
The survey, which gathered responses from 1,500 women in February 2025, indicates that nearly 21% have postponed or avoided menopause treatment due to financial constraints. Additionally, 12% reported making financial trade-offs, such as reducing spending on essential goods, to budget for their healthcare needs. This situation underscores an unfortunate disparity in access to menopause treatment, an experience that affects all women.
Experiencing Menopause: Symptoms and Treatment Options
Menopause often presents with symptoms that greatly disrupt daily life for women. The survey highlights that 50% of participants reported experiencing hot flashes and night sweats, while sleep disturbances impacted 42%. Other common symptoms include weight gain (41%) and mood changes (39%).
Despite the availability of various treatment options, only a small fraction of women turn to menopausal hormone therapy (MHT), commonly regarded as the most effective intervention for severe symptoms. The survey reveals that only 7.2% utilize MHT, while non-MHT prescription medication use is even lower at 3.7%. Interestingly, 8.1% opt for nonprescription supplements as an alternative.
Costs Associated with Menopause Management
The financial burden associated with menopause management is significant. When surveyed about their expenditures on treatments, responses showed:
- Prescription Medications: 76% of women spend less than $50 monthly; 19% spend between $50 and $100; and 5.4% exceed $100.
- OTC Treatments: 84% spend under $50 per month, with 14% paying up to $100.
- Supplements: 23% spend between $50 and $100, with 5% spending over $100.
Financial strain is a common theme, with 41% of women indicating they experience some level of financial burden related to prescription medications. Among these, 21% described the costs as “very burdensome.” Although OTC treatments and supplements offered slightly better affordability, 42% still found them difficult to manage financially.
Challenges Related to Insurance Coverage
The survey highlights a critical issue: lack of comprehensive insurance coverage for menopause-related treatments. Only 26% of respondents reported that their prescriptions were fully covered by insurance. A substantial 60% had to pay a copay, while 8% faced no insurance coverage whatsoever, leading to various alternative payment strategies:
- 16% relied on discount cards to alleviate costs.
- 14% paid entirely out-of-pocket without any discounts.
This lack of robust insurance translates to significant out-of-pocket expenses, particularly for women managing several prescriptions or pursuing long-term treatment plans.
The Impact of Financial Strain on Treatment Decisions
For many women, the financial implications of menopause treatment necessitate difficult choices. Among those who have reduced or stopped medications, 10% cited cost as the primary reason. Additionally, the survey reflects that 21% have either postponed or foregone menopause-related care due to financial worries.
The potential consequences of untreated menopause symptoms raise serious health concerns. Lack of proper management can lead to increased risks for osteoporosis, heart disease, and diminished quality of life in the long term. The reality that some women must choose between financial stability and adequate healthcare underscores significant gaps in the current healthcare landscape, particularly affecting midlife women. The findings call for a heightened focus on enhancing insurance coverage and expanding access to affordable treatment options.
Methodological Note
The findings are based on a survey conducted by GoodRx through YouGov from February 22 to February 28, 2025. The sample included adult women experiencing perimenopause or menopause, with a total of 1,500 responses analyzed. Participants were screened based on their medical diagnosis or age, ensuring relevant insights into the menopause experience.
